# US 11,304,925 B1 · Cannabis composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,925 B1
- Document ID: US11304925B1
- Status: Granted
- Kind: B1
- Application number: 15/780,579
- Filed: 2017-08-03
- Granted: 2022-04-19
- Earliest claimed: 2016-08-03
- Assignees: Zelda Therapeutics Operations Pty Ltd.
- Applicants: Zelda Therapeutics Operations Pty Ltd
- Inventors: Harry Karelis; Mara Gordon; Stewart Smith; Stewart Washer
- Web page: https://patentgrep.com/patent/US11304925B1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/01: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 36/3482: {Cannabis}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a method for treating cancer or a symptom associated with cancer. In particular, the present invention relates to a method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract that comprises Δ9-tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.

## Claims

### Claim 1

A pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a cannabinoid fraction and a terpene fraction, wherein the Cannabis extract comprises:
A:
≥0.3% w/w of the terpene fraction;
≥50% w/w Δ9-Tetrahydrocannabinol (THC);
≥0.3% w/w Cannabigerol (CBG); and
≤0.5% w/w Cannabinol (CBN);
wherein the terpene fraction comprises:
ß-caryophyllene in an amount of at least 11% by weight of the terpene fraction,
linalool in an amount of at least 5% by weight of the terpene fraction; and
ß-pinene in an amount of at least 1% by weight of the terpene fraction.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Cannabis extract is a Cannabis oil.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein, for composition A, the Cannabis extract comprises Δ9-tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Cannabis extract comprises one or more additional cannabinoids selected from Δ9-Tetrahydrocannabinolic acid (THCA), Δ9-Tetrahydrocannabivarin (THCV), and (−)-Cannabidivarin (CBDV).

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the terpene fraction further comprises one or more of ß-myrcene, D-limonene, a nerolidol and α-pinene.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the terpene fraction further comprises one or more of α-bisabolol, caryophyllene oxide, p-cymene, isopulegol, ocimene, α-terpinene, γ-terpinene, δ-s-carene, guaiol, and terpinolene.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is sesame oil.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an active agent other than the Cannabis extract.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 for treating cancer or a symptom associated with cancer.